Securities Registration: Employee Benefit Plan (s-8)
March 01 2021 - 4:35PM
Edgar (US Regulatory)
As filed with the Securities
and Exchange Commission on March 1, 2021
Registration No. 333-
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM S-8
REGISTRATION STATEMENT
UNDER
THE SECURITIES ACT OF 1933
CARA THERAPEUTICS, INC.
(Exact name of registrant as specified
in its charter)
Delaware
|
|
75-3175693
|
(State of incorporation or organization)
|
|
(I.R.S. Employer Identification No.)
|
4 Stamford Plaza
|
|
|
107 Elm Street, 9th Floor
|
|
|
Stamford, Connecticut
|
|
06902
|
(Address of principal executive office)
|
|
(Zip Code)
|
2014 Equity Incentive Plan
(Full title of the plans)
Derek Chalmers, Ph.D., D.Sc.
Chief Executive Officer Cara Therapeutics, Inc.
4 Stamford Plaza
107 Elm Street, 9th Floor
Stamford, Connecticut (203) 406-3700
(Name, address and telephone number,
including area code, of agent for service)
Copies to:
Babak Yaghmaie
Darren DeStefano
Brandon Fenn
Cooley LLP
55 Hudson Yards
New York, NY 10001
(212) 479-6000
Indicate by check mark whether the Registrant
is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth
company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting
company” and “emerging growth company” in Rule 12b-2 of the Exchange Act. (Check one):
Large Accelerated filer x
|
Accelerated filer ¨
|
|
|
Non-accelerated filer ¨ (Do not check if a smaller reporting company)
|
Smaller reporting company ¨
|
Emerging growth company ¨
If an emerging growth company, indicate by check mark if the
Registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards
provided pursuant to Section 7(a)(2)(B) of the Securities Act. ¨
CALCULATION OF REGISTRATION FEE
Title of
Securities
|
Amount
To Be
Registered (1)
|
Proposed
Maximum
Offering Price
Per Share
|
Proposed
Maximum
Aggregate
Offering Price
|
Amount of
Registration
|
Common Stock, $0.001 par value per share
|
1,496,166(2)
|
$19.15(3)
|
$28,651,578.90
|
|
$3,126
|
|
(1)
|
Pursuant to Rule 416(a) under the Securities Act of 1933, as amended (the “Securities Act”),
this Registration Statement shall also cover any additional shares of the Registrant’s common stock that become issuable
in respect of the securities identified in the above table by reason of any stock dividend, stock split, recapitalization or other
similar transaction effected without the Registrant’s receipt of consideration which results in an increase in the number
of the outstanding shares of the Registrant’s common stock.
|
|
(2)
|
Represents additional shares of the Registrant’s common stock reserved for issuance under the Registrant’s 2014
Equity Incentive Plan resulting from the automatic annual increase on January 1 of each year from January 1, 2015 through
January 1, 2024 by the lesser of (a) 3% of the total number of shares of the Registrant’s Common Stock outstanding
on December 31 of the preceding calendar year and (b) a number of shares determined by the Registrant’s board of
directors.
|
|
(3)
|
Estimated pursuant to Rules 457(c) and (h) of the Securities Act, solely for the purpose of calculating the
registration fee, on the basis of the average of the high and low prices of the Registrant’s common stock as reported on
the Nasdaq Global Market on February 26, 2021.
|
REGISTRATION OF ADDITIONAL SHARES
PURSUANT TO
GENERAL INSTRUCTION E
Pursuant to General Instruction E of Form S-8,
Cara Therapeutics, Inc. (the “Registrant”) is filing this Registration Statement with the Securities
and Exchange Commission (the “Commission”) to register 1,496,166 additional shares of its Common Stock
under the Registrant’s 2014 Equity Incentive Plan, pursuant to the provisions of the 2014 Equity Incentive Plan providing
for an automatic increase in the number of shares reserved and available for issuance under the 2014 Equity Incentive Plan on January 1,
2021. In accordance with the instructional note to Part I of Form S-8 as promulgated by the Commission, the information
specified by Part I of the Form S-8 has been omitted from this Registration Statement.
PART II
INFORMATION REQUIRED IN THE REGISTRATION
STATEMENT
|
Item 3.
|
Incorporation of Documents by Reference.
|
The following documents filed by the Registrant
with the Commission are incorporated by reference into this Registration Statement:
|
(a)
|
The contents of the Registrant’s Registration Statements on Form S-8, filed with the
Commission on February 12, 2014 (Registration No. 333-193905), March 27, 2015 (Registration No. 333-203057),
March 11, 2016 (Registration No.333-210096), March 10, 2017 (Registration No. 333-216606), March 16, 2018 (Registration No. 333-223726), March 15, 2019 (Registration No. 333-230335), and February 28, 2020 (Registration No. 333-236728).
|
|
(c)
|
All other reports filed by the Company pursuant to Section 13(a) or Section 15(d) of the Exchange Act of
1934, as amended (the “Exchange Act”) since December 31, 2020.
|
All other reports and documents subsequently
filed by the Registrant pursuant to Sections 13(a), 13(c), 14 and 15(d) of the Exchange Act (other than Current Reports furnished
under Item 2.02 or Item 7.01 of Form 8-K and exhibits furnished on such form that relate to such items) on or after the date
of this Registration Statement and prior to the filing of a post-effective amendment to this Registration Statement which indicates
that all securities offered have been sold or which deregisters all securities then remaining unsold, shall be deemed to be incorporated
by reference herein and to be a part of this Registration Statement from the date of the filing of such reports and documents.
Any statement contained in a document incorporated or deemed to be incorporated by reference herein shall be deemed to be modified
or superseded for purposes of this Registration Statement to the extent that a statement contained herein or in any subsequently
filed document that also is deemed to be incorporated by reference herein modifies or supersedes such statement. Any such statement
so modified or superseded shall not be deemed, except as so modified or superseded, to constitute a part of this Registration Statement.
Exhibit
|
|
Number
|
Description of Document
|
|
(1)
|
Filed as Exhibit 3.1 to the Registrant’s Current Report on Form 8-K (File No. 001-36279) filed with the
Commission on February 7, 2014 and incorporated herein by reference.
|
|
(2)
|
Filed as Exhibit 3.2 to the Registrant’s Current Report on Form 8-K (File No. 001-36279) filed with the
Commission on February 7, 2014 and incorporated herein by reference.
|
|
(3)
|
Filed as Exhibit 4.1 to Pre-effective Amendment No. 2 to the Registrant’s Registration Statement on Form S-1
Registration No. 333-192230) filed with the Commission on January 17, 2014 and incorporated herein by reference.
|
|
(4)
|
Filed as Exhibit 10.3 to Pre-effective Amendment No. 2 to the Registrant’s Registration Statement on Form S-1
Registration No. 333-192230) filed with the Commission on January 17, 2014 and incorporated herein by reference.
|
|
(5)
|
Filed as Exhibit 10.3.1 to Pre-effective Amendment No. 2 to the Registrant’s Registration Statement on Form S-1
Registration No. 333-192230) filed with the Commission on January 17, 2014 and incorporated herein by reference.
|
|
(6)
|
Filed as Exhibit 10.3.2 to Pre-effective Amendment No. 2 to the Registrant’s Registration Statement on Form S-1
Registration No. 333-192230) filed with the Commission on January 17, 2014 and incorporated herein by reference.
|
SIGNATURES
Pursuant to the requirements
of the Securities Act of 1933, as amended, the Registrant certifies that it has reasonable grounds to believe that it meets all
of the requirements for filing on Form S-8 and has duly caused this Registration Statement to be signed on its behalf by the
undersigned, thereunto duly authorized, in the Town of Stamford, State of Connecticut, on March 1, 2021.
|
CARA THERAPEUTICS, INC.
|
|
|
|
By:
|
/s/ Derek Chalmers, Ph.D., D.Sc.
|
|
|
Derek Chalmers, Ph.D., D.Sc.
|
|
|
President and Chief Executive Officer
|
POWER OF ATTORNEY
KNOW ALL PERSONS BY THESE PRESENTS,
that each of the persons whose names appear below constitutes and appoints Derek Chalmers, Ph.D., D.Sc. and Thomas Reilly, and
each of them, such person’s true and lawful attorney in fact and agent, with full power of substitution and re-substitution,
for and in such person’s name, place and stead, in any and all capacities, to execute any and all amendments (including post-effective
amendments) to this Registration Statement (or any other registration statement for the same offering that is to be effective upon
filing pursuant to Rule 462(b) under the U.S. Securities Act of 1933), and to file the same, together with all exhibits
thereto, and other documents in connection therewith, with the U.S. Securities and Exchange Commission, and such other agencies,
offices and persons as may be required by applicable law, granting unto said attorney in fact and agent, full power and authority
to do and perform each and every act and thing requisite or necessary to be done in and about the premises, as fully to all intents
and purposes as such person might or could do in person, hereby ratifying and confirming all that each said attorney-in-fact and
agent may lawfully do or cause to be done by virtue hereof.
Pursuant to the requirements of the Securities
Act of 1933, this registration statement has been signed by the following persons in the capacities and on the dates indicated.
|
|
|
|
|
Signature
|
|
Title
|
|
Date
|
|
|
|
|
|
/s/ Derek Chalmers, Ph.D., D.Sc.
|
|
President, Chief Executive Officer and Director
|
|
March 1, 2021
|
Derek Chalmers, Ph.D., D.Sc.
|
|
(Principal Executive Officer)
|
|
|
|
|
|
|
|
/s/ Thomas Reilly
|
|
Chief Financial Officer
|
|
March 1, 2021
|
Thomas Reilly
|
|
(Principal Financial and Accounting Officer)
|
|
|
|
|
|
|
|
/s/ Martin Vogelbaum
|
|
Director
|
|
March 1, 2021
|
Martin Vogelbaum
|
|
|
|
|
|
|
|
|
|
/s/ Harrison M. Bains, Jr.
|
|
Director
|
|
March 1, 2021
|
Harrison M. Bains, Jr.
|
|
|
|
|
|
|
|
|
|
/s/ Jeffrey Ives, Ph.D.
|
|
Director
|
|
March 1, 2021
|
Jeffrey Ives, Ph.D.
|
|
|
|
|
|
|
|
|
|
/s/ Christopher Posner
|
|
Director
|
|
March 1, 2021
|
Christopher Posner
|
|
|
|
|
|
|
|
|
|
/s/ Susan Shiff, Ph.D.
|
|
Director
|
|
March 1, 2021
|
Susan Shiff, Ph.D.
|
|
|
|
|
Cara Therapeutics (NASDAQ:CARA)
Historical Stock Chart
From Mar 2024 to Apr 2024
Cara Therapeutics (NASDAQ:CARA)
Historical Stock Chart
From Apr 2023 to Apr 2024